Cadence Neuroscience

Cadence Neuroscience is a medical device company based in Redmond, Washington, founded in 2017.

The company focuses on developing personalized neuromodulation therapies for drug-resistant epilepsy and other neurological disorders, particularly for pediatric and adult patients. Their primary product is the Biomarker Targeted Stimulation (BTS) device, which detects specific brain signals associated with seizures and delivers targeted electrical stimulation to interrupt seizure progression. The BTS device aims to provide a less invasive alternative to traditional surgical treatments, offering personalized, adaptive therapy based on each patient's unique brain activity. Cadence Neuroscience is currently conducting pivotal clinical trials to support regulatory approval from the U.S. Food and Drug Administration (FDA). With a mission to transform patient care, the company seeks to enable individuals to live seizure-free lives through innovative treatment options.